Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors by Crooks, Peter A. et al.
University of Kentucky
UKnowledge
Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences
9-30-2014
Mono Quaternary Ammonium Salts and Methods
for Modulating Neuronal Nicotinic Acetylcholine
Receptors
Peter A. Crooks
University of Kentucky, pcrooks@uky.edu
Linda P. Dwoskin
University of Kentucky, ldwoskin@email.uky.edu
Guangrong Zheng
University of Kentucky, guangrong.zheng@uky.edu
Sangeetha Sumithran
University of Kentucky
Zhenfa Zheng
University of Kentucky, zhangzhenfa@uky.edu
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/ps_patents
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in
Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Recommended Citation
Crooks, Peter A.; Dwoskin, Linda P.; Zheng, Guangrong; Sumithran, Sangeetha; and Zheng, Zhenfa, "Mono Quaternary Ammonium
Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors" (2014). Pharmaceutical Sciences Faculty Patents. 23.
https://uknowledge.uky.edu/ps_patents/23
USOO8846937B2 
(12) United States Patent (10) Patent N0.: US 8,846,937 B2 
Crooks et a]. (45) Date of Patent: Sep. 30, 2014 
(54) MONO QUATERNARY AMMONIUM SALTS (52) US. C]. 
AND METHODS FOR MODULATING CPC .......... .. C07D 213/20 (2013.01); C07D 213/30 
NEURONAL NICOTINIC ACETYLCHOLINE (2013-01); C07D 217/10 (2013-01); C070 
RECEPTORS 215/10 (2013.01); C07C 17/16 (2013.01); 
C07D 401/06 (2013.01) 
Inventors; Peter Crooks, Nicholasv?le’ ......................................... .. 
Linda P. Dwoskin, Lexington, KY (US); (58) Field of Classi?cation Search 
None Guangrong Zheng, Lexington, KY 
(US); Sangeetha Sumithran, Lexington, 
KY (US); Zhenfa Zheng, Lexington, 
KY (US) 
(73) Assignee: University of Kentucky Research 
Foundation, Lexington, KY (US) 
( * ) Notice: Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 226 days. 
(21) Appl. No.: 12/304,955 
(22) PCT Filed: Jun. 15, 2007 
(86) PCT No.: PCT/US2007/014192 
§ 371 (0X1)’ 
(2), (4) Date: Jan. 4, 2010 
(87) PCT Pub. No.: WO2007/149392 
PCT Pub. Date: Dec. 27, 2007 
(65) Prior Publication Data 
US 2010/0113511 A1 May 6,2010 
Related US. Application Data 
(60) Provisional application No. 60/814,423, ?led on Jun. 
16, 2006. 
(51) Int. Cl. 
A61K 31/435 (2006.01) 
00 7D 213/18 (2006.01) 
00 7D 213/30 (2006.01) 
C07D 21 7/10 (2006.01) 
00 7D 213/20 (2006.01) 
C07D 215/10 (2006.01) 
C07C 17/16 (2006.01) 
C07D 401/06 (2006.01) 
See application ?le for complete search history. 
(56) References Cited 
U.S. PATENT DOCUMENTS 
3/2006 ReitZ et al. 
2005/0215571 A1 9/2005 Romano 
2005/0282823 A1 12/2005 Breining et al. 
OTHER PUBLICATIONS 
7,018,797 B2 
Silverman, R. “The Organic Chemistry of Drug Design and Drug 
Action,” 2004, Elsevier, pp. 29-32.* 
HCAPLUS 1988:565166.* 
HCAPLUS 1993: 249523.* 
Ayers, J. et al., Bioorg. Med. Chem. Lett. (2002), vol. 12(21), pp. 
3067-3071.* 
Bergmeier, S. et a1., Bioorg. Med. Chem. Lett.(l999), v01. 9, pp. 
2263-2266.* 
Allen, D. et al, J. Pharmacol Exp. Thera, 2003, vol. 304, pp. 1268 
1274* 
Olbrich, C. et al., J. Nanopart. Res., 2002, vol. 4, pp. 121-129.* 
Grinevich, V. et al., J. Pharmacol. Exper. Thera. 2003, vol. 306, pp. 
1011-1020.* 
Dwoskin, L., et al., Bioorganic & Medicinal Chemistry Letters 2004, 
vol. 14(8), pp. 1863-1867.* 
International Search Report dated Nov. 23, 2007 (One (1) page). 
* cited by examiner 
Primary Examiner * Heidi Reese 
(74) Attorney, Agent, or Firm * Crowell & Moring LLP 
(57) ABSTRACT 
Provided are monoquatemary ammonium compounds Which 
are modulators ofnicotinic acetylcholine receptors. Also pro 
vided are methods of using the compounds for modulating the 
function of a nicotinic acetylcholine receptor, and for the 
prevention and/ or treatment of central nervous system disor 
ders, substance use and/ or abuse, and or gastrointestinal tract 
disorders. 
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MONO QUATERNARY AMMONIUM SALTS 
AND METHODS FOR MODULATING 
NEURONAL NICOTINIC ACETYLCHOLINE 
RECEPTORS 
This application claims bene?t of US. Provisional Appli 
cation No. 60/814,423, ?led Jun. 16, 2006, Which is incorpo 
rated herein by reference in its entirety. 
IDENTIFICATION OF FEDERAL FUNDING 
The present invention was supported by Grant NIH 
Ul9DA017548 from the National Institutes of Health, and 
therefore the government may have rights in the invention. 
FIELD OF THE INVENTION 
The invention relates to monoquaternary ammonium salts 
and their use in modulating nicotinic acetylcholine receptors. 
BACKGROUND OF THE INVENTION 
S(—)-nicotine (N IC) activates presynaptic andpostsynaptic 
neuronal nicotinic receptors that evoke the release of neu 
rotransmitters from presynaptic terminals and that modulate 
the depolarization state of the postsynaptic neuronal mem 
brane, respectively. Thus, nicotine produces its effect by 
binding to a family of ligand-gated ion channels, stimulated 
by acetylcholine (ACh) or nicotine Which causes the ion 
channel to open and cations to ?ux With a resulting rapid 
(millisecond) depolarization of the target cell. 
Neuronal nicotinic receptors are composed of two types of 
subunits, 0t and [3, and assemble as heteromeric receptors With 
the general stoichiometry of 2a and 3[3 or as homomeric 
receptors With 5a subunits. Nine subtypes of the ct subunit 
(a2 to (x10) and three subtypes of the [3 unit ([32 to [34) are 
found in the central nervous system. The mo st common nico 
tinic receptor subtype in the brain is composed of two (x4 and 
three [32 subunits, i.e., (x4[32. These subunits display different, 
but overlapping, patterns of expression in the brain. Examples 
of heteromeric receptor subtypes include (x4[32, (x3[32, (x3 [34, 
(x6[32, (x40t5[32, (x60t5[32, (x40t6[32, (x4[32[34, (x3[32[34, and 
others. The predominant homomeric subtype includes (x7, but 
other combinations have also been proposed. 
For the most part, the actual subunit compositions and 
stoichiometries of nicotinic receptors in the brain remain to 
be elucidated. Thus, neuronal nicotinic receptor subtype 
diversity originates from differences in the amino acid 
sequence at the subunit level and from the multiple combina 
tions of assemblies of subunits into functional receptor pro 
teins, Which affords a Wide diversity of pharmacological 
speci?city. 
In spite of the extensive diversity in neuronal nicotinic 
receptor messenger RNA expression, only a limited number 
of tools are available to study the pharmacology of native 
receptors. Radioligands are used in many studies. [3H]NIC 
appears to label the same sites in the brain as [3H]ACh. It has 
been estimated that over 90% of [3H]NIC binding in the brain 
is due to association With the heteromeric receptor that is 
composed of a4 and [32 subunits. Also abundant in the central 
nervous system are the homomeric receptors labeled by [3 H] 
methyllycaconitine (MLA), Which has high af?nity for the (x7 
nicotinic receptor subtype. Nicotinic receptor subtypes can 
be studied using functional assays, such as NIC-evoked neu 
rotransmitter release (e.g., [3H]dopamine (DA) release, [3 H] 
norepinephrine (NE) release, [3H]serotonin (5-HT) release, 
[3 H] gamma-aminobutyric acid (GABA) release and [3 H] 
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glutamate release) from superfused rat brain slices. Nicotinic 
receptors are located in the cell body and terminal areas of 
these neurotransmitter systems. NIC facilitates neurotrans 
mitter release from nerve terminals. 
The structural and functional diversity of central nervous 
system nicotinic receptors has stimulated a great deal of inter 
est in developing novel, subtype-selective agonists and/or 
antagonists. Some of these agonists are currently being evalu 
ated in clinical trials for cognitive enhancement and neuro 
protective effects, potentially bene?cial for disease states 
such as Alzheimer’s and Parkinson’s disease. 
SUMMARY OF THE INVENTION 
In one embodiment, compounds corresponding to the fol 
lowing structure are provided. 
(1) 
A1, A2, A3, A4, and A5 are independently selected from 
nitrogen or carbon, provided that When nitrogen is present, 
the nitrogen does not have an R substituent attached. 
R1, R2, R3, R4, and R5 are each independently selected 
from the group consisting of hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
heterocycle, substituted heterocycle, halo, cyano, and nitro, 
or R1 and R2 or R2 and R3 together With the carbons to Which 
they are attached independently form a three to eight-member 
cycloalkane, substituted cycloalkane, cycloalkene, substi 
tuted cycloalkene, aryl, substituted aryl, heterocycle With one 
to three hetero atoms in the ring, or substituted heterocycle 
With one to three hetero atoms in the ring. 
Z1 is absent or is selected from the group consisting of 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
phenylene, substituted phenylene, alkoxy, and substituted 
alkoxy. 
Z2 is selected from the group consisting of alkyl, substi 
tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, sub 
stituted alkenyl, alkynyl, substituted alkynyl, arylene, substi 
tuted arylene, heterocycle, substituted heterocycle, alkoxy, 
and substituted alkoxy. 
Z3 is selected from is selected from hydrogen, alkyl, sub 
stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substi 
tuted aryl, heterocycle, and substituted heterocycle. 
X‘ is an inorganic or organic anion. 
In another embodiment, a composition is provided com 
prising a pharmaceutically acceptable carrier and a com 
pound as described above. 
In another embodiment, a method is provided for selec 
tively modulating the function of a nicotinic acetylcholine 
receptor comprising administering a therapeutically effective 
amount of a compound as described above to a mammalian 
subject in need thereof. 
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In another embodiment, a method is provided for prevent 
ing and/ or treating a central nervous system associated disor 
der comprising administering a therapeutically effective 
amount of a compound as described above to a mammalian 
subject in need thereof. 
In another embodiment, a method is provided for prevent 
ing and/or treating substance use and/or abuse comprising 
administering a therapeutically effective amount of a com 
pound as described above to a mammalian subject in need 
thereof. 
In another embodiment, a method is provided for prevent 
ing and/or treating gastrointestinal tract disorders comprising 
administering a therapeutically effective amount of a com 
pound as described above to a mammalian subject in need 
thereof. 
Other methods, features and advantages of the present 
invention will be or become apparent to one with skill in the 
art upon examination of the following detailed descriptions. It 
is intended that all such additional methods, features and 
advantages be included within this description, be within the 
scope of the present invention, and be protected by the accom 
panying claims. 
DETAILED DESCRIPTION OF THE INVENTION 
Before the present compositions and methods are 
described, it is to be understood that the invention is not 
limited to the particular methodologies, protocols, assays, 
and reagents described, as these may vary. It is also to be 
understood that the terminology used herein is intended to 
describe particular embodiments of the present invention, and 
is in no way intended to limit the scope of the present inven 
tion as set forth in the appended claims. 
It must be noted that as used herein and in the appended 
claims, the singular forms “a,” “an,” and “the” include plural 
references unless the context clearly dictates otherwise. 
Unless de?ned otherwise, all technical and scienti?c terms 
used herein have the same meanings as commonly under 
stood by one of ordinary skill in the art to which this invention 
belongs. All publications cited herein are incorporated herein 
by reference in their entirety for the purpose of describing and 
disclosing the methodologies, reagents, and tools reported in 
the publications that might be used in connection with the 
invention. Nothing herein is to be construed as an admission 
that the invention is not entitled to antedate such disclosure by 
virtue of prior invention. 
The term “nicotinic acetylcholine receptor” refers to the 
endogenous acetylcholine receptor having binding sites for 
acetylcholine which also bind to nicotine. The term “nicotinic 
acetylcholine receptor” includes the term “neural nicotinic 
acetylcholine receptor.” 
The terms “subtype of nicotinic acetylcholine receptor,” 
and “nicotinic acetylcholine receptor subtype” refer to vari 
ous subunit combinations of the nicotinic acetylcholine 
receptor, and may refer to a particular homomeric or hetero 
meric complex, or multiple homomeric or heteromeric com 
plexes. 
The term “agonist” refers to a substance which interacts 
with a receptor and increases or prolongs a physiological 
response (i.e. activates the receptor). 
The term “partial agonist” refers to a substance which 
interacts with and activates a receptor to a lesser degree than 
an agonist. 
The term “antagonist” refers to a substance which interacts 
with and decreases the extent or duration of a physiological 
response of that receptor. 
5 
20 
25 
30 
35 
40 
50 
55 
60 
65 
4 
The terms “disorder,” “disease,” and “condition” are used 
inclusively and refer to any status deviating from normal. 
The term “central nervous system associated disorders” 
includes any cognitive, neurological, and mental disorders 
causing aberrant or pathological neural signal transmission, 
such as disorders associated with the alteration of normal 
neurotransmitter release in the brain. 
The term “lower alkyl” refers to straight or branched chain 
alkyl radicals having in the range of l to 4 carbon atoms. 
The term “alkyl” refers to straight or branched chain alkyl 
radicals having 1 to 19 carbon atoms, and “substituted alkyl” 
refers to alkyl radicals further bearing one or more substitu 
ents including, but not limited to, hydroxy, alkoxy (of a lower 
alkyl group), mercapto (of a lower alkyl group), aryl, hetero 
cyclic, halogen, tri?uoromethyl, cyano, nitro, amino, car 
boxyl, carbamate, sulfonyl, and sulfonamide. 
The term “cycloalkyl” refers to cyclic ring-containing moi 
eties containing 3 to 8 carbon atoms, and “substituted 
cycloalkyl” refers to cycloalkyl moieties further bearing one 
or more substituents as set forth above. 
The term “alkenyl” refers to straight or branched chain 
hydrocarbyl groups having at least one carbon-carbon double 
bond and having 2 to 19 carbon atoms, and “substituted 
alkenyl” refers to alkenyl groups further bearing one or more 
substituents as set forth above. 
The term “alkynyl” refers to straight or branched chain 
hydrocarbyl moieties having at least one carbon-carbon triple 
bond and having 2 to 19 carbon atoms, and “substituted 
alkynyl” refers to alkynyl moieties further bearing one or 
more substituents as set forth above. 
The term “aryl” refers to aromatic groups having 6 to 24 
carbon atoms, and “substituted aryl” refers to aryl groups 
further bearing one or more substituents as set forth above. 
The term “heterocyclic” refers to cyclic moieties contain 
ing one or more heteroatoms as part of the ring structure and 
having 3 to 24 carbon atoms, and “substituted heterocyclic” 
refers to heterocyclic moieties further bearing one or more 
substituents as set forth above. 
The term “halogen” refers to ?uoride, chloride, bromide or 
iodide groups. It is understood that in all substituted groups 
de?ned above, polymers arrived at by de?ning substituents 
with further substituents to themselves (e.g. substituted aryl 
having a substituted aryl group as a substituent which is itself 
substituted with a substituted aryl group, etc.) are not 
intended for inclusion herein. In such cases, the maximum 
number of such substituents is three. That is to say that each 
of the above de?nitions is constrained by a limitation that, for 
example, substituted aryl groups are limited to -substituted 
aryl-(substituted aryl)-substituted aryl. 
Compounds of the present invention are mono quaternary 
ammonium salts corresponding to Formula (I): 
(1) 
A1, A2, A3, A4, and A5 are independently selected from 
nitrogen or carbon, provided that when nitrogen is present, 
the nitrogen does not have an R substituent attached. 
US 8,846,937 B2 
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R1, R2, R3, R4, and R5 are each independently selected 
from the group consisting of hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
heterocycle, substituted heterocycle, halo, cyano, and nitro, 
or R1 and R2 or R2 and R3 together With the carbons to Which 
they are attached independently form a three to eight-member 
cycloalkane, substituted cycloalkane, cycloalkene, substi 
tuted cycloalkene, aryl, substituted aryl, heterocycle With one 
to three hetero atoms in the ring, or substituted heterocycle 
With one to three hetero atoms in the ring. 
Z1 is absent or is selected from the group consisting of 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
phenylene, substituted phenylene, alkoxy, and substituted 
alkoxy. 
Z2 is selected from the group consisting of alkyl, substi 
tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, sub 
stituted alkenyl, alkynyl, substituted alkynyl, arylene, sub sti 
tuted arylene, heterocycle, substituted heterocycle, alkoxy, 
and substituted alkoxy. 
Z3 is selected from is selected from hydrogen, alkyl, sub 
stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
sub stituted alkenyl, alkynyl, substituted alkynyl, aryl, sub sti 
tuted aryl, heterocycle, and substituted heterocycle. 
X‘ is an inorganic or organic anion. 
For example, R1, R2, R3, R4, and R5 include hydrogen, 
methyl, ethyl, propyl, butyl, tri?uoromethyl, pyrrolidine, 
N-alkyl pyrrolidine (for example Where the alkyl chain is 
methyl, ethyl or propyl), unsaturated pyrrolidine, unsaturated 
N-alkyl pyrrolidine (for example Where the alkyl chain is 
methyl, ethyl or propyl), aziridine, N-methyl aziridine, aze 
tidine, N-methyl azetidine, unsaturated azetidine, unsatur 
ated N-methyl azetidine, piperidine, N-methyl piperidine, 
unsaturated piperidine, unsaturated N-methyl piperidine, 
azepane, N-methyl azepane, unsaturated azepane, unsatur 
ated N-methyl azepane, azocane, N-methyl azocane, unsat 
urated azocane, unsaturated N-methyl azocane, l-aza-bicy 
clo[3.2.l]octane, l-aza-bicyclo[2.2.l]heptane, 8-methyl-8 
aza-bicyclo[3 .2. l]octane, l-aza-tricyclo[3.3.1.13’7]decane, 
methyl cycloalkyl, methyl substituted cycloalkyl, methylpyr 
rolidine, methyl N-alkyl pyrrolidine (for example Where the 
alkyl chain is methyl, ethyl or propyl), methyl unsaturated 
pyrrolidine, methyl unsaturated N-alkyl pyrrolidine (for 
example Where the alkyl chain is methyl, ethyl or propyl), 
methyl aZiridine, methyl N-methyl aZiridine, methyl azeti 
dine, methyl N-methyl azetidine, methyl unsaturated azeti 
dine, methyl unsaturated N-methyl azetidine, methyl piperi 
dine, methyl N-methyl piperidine, methyl unsaturated 
piperidine, methyl unsaturated N-methyl piperidine, methyl 
azepane, methyl N-methyl azepane, methyl unsaturated 
azepane, methyl unsaturated N-methyl azepane, methyl azo 
cane, methyl N-methyl azocane, methyl unsaturated azocane, 
methyl unsaturated N-methyl azocane, methyl-l -aza-bicyclo 
[3.2.1]octane, methyl-l-aza-bicyclo[2.2.l]heptane, 8-me 
thyl-8-aza-bicyclo [3.2.1]octane, and methyl-l-aza-tricyclo 
[3.3.1.13’7]decane. 
As another example, when R1 and R2, or R2 and R3 together 
With the carbons to Which they are attached, independently 
form a three to eight-membered ring, that ring may be a 
heterocycle containing up to three hetero atoms (for example 
nitrogen, oxygen or sulfur) in the ring, and further may be 
substituted With one or more substituents. For example, pos 
sible rings include benzene, pyridine, pyran, indene, isoin 
dene, benzofuran, isobenzofuran, benzo[b]thiophene, benzo 
[c]thiophene, indole, indolenine, isoindole, cyclopental[b] 
pyridine, pyrano[3,4-b]pynrole, indazole, indovaine, 
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benzoxazole, anthranil naphthalene, tetralin, decalin, 
chromene, coumarin, chroman-4-one, isocoumarin, isoch 
romen-3 -one, quinoline, isoquinoline, cinnoline, quinazo 
line, naphthyrdine, pyrido[3 ,4-b] -pyridine, pyridol [3 ,2-b]py 
ridine, pyrido[4,3,-b]-pyridine, benzovaine, anthracene, 
phenanthrene, phenalene, ?uorene, carazole, xanthene, acni 
dine, octahydro-[l]pyridine, l-methyloctahydro-[l]pyrdine, 
octahydroindole, l-methyloctahydro-indole, octahydro-cy 
clopenta[b]pyrrole, l-methyloctahydro-cyclopenta[b]pyr 
role, decahydroquinoline, or l-methyldecahydroquinoline. 
As a further example, heterocycles formed by A1, A2, A3, 
A4, and A5 in combination With R1, R2, R3 , R4, and R5 include 
pyridine, quinoline, 5,6,7,8-tetrahydroquinoline, isoquino 
line, tetrahydroisoquinoline, pyraZine, pyrimidine, 
pyridaZine, and triaZine, as well as substituted forms thereof. 
Z1 for example includes alkyl (for example butyl or pentyl), 
cis-alkenyl; trans-alkenyl; substituted cis-alkenyl; substi 
tuted trans-alkenyl; alkynyl (for example but-3-ynyl or pent 
4-ynyl). 
Z2 for example includes cis-alkenyl, trans-alkenyl, substi 
tuted cis-alkenyl, and substituted trans-alkenyl. 
X‘ for example includes Cl‘, Br‘, I‘, N021 HSO4_, 804—, 
HPO4_, PO42“, ethanesulfonate, tri?uoromethane sulfate, 
p-toluenesulfonate, benzenesulfonate, salicylate, proprion 
ate, ascorbate, aspartate, fumarate, galactarate, maleate, cit 
rate, glutamate, glycolate, lactate, malate, maleate, tartrate, 
oxalate, succinate, or similar pharmaceutically acceptable 
organic acid addition salts, including the pharmaceutically 
acceptable salts listed in the Journal of Pharmaceutical Sci 
ences volume 66, page 2, 1977, Which are hereby incorpo 
rated by reference. The above salt forms may be in some cases 
hydrates or solvates With alcohols and other solvents. 
In a compound of Formula (I), preferably A1, A2, A3, A4, 
and A5 are carbon. 
In a compound of Formula (I), preferably R1 is hydrogen, 
alkyl, or forms a six membered ring With A1, A2 and R2 and 
with R1 and R2 providing four carbon atoms. More preferably, 
R1 is selected from hydrogen, methyl, forms a six membered 
ring With A1, A2 and R2 and with R1 and R2 providing four 
unsaturated carbon atoms, or forms a phenyl group With A1, 
A2 and R2. 
In a compound of Formula (I), preferably R2 is hydrogen, 
alkyl, aryl, 3-hydroxypropyl, l-methyl-2-pyrrolidinyl, halo, 
forms a six membered ring WithAl , A2 and R1 and with R1 and 
R2 providing four carbon atoms, or forms a six membered 
ring With A2, A3 and R3 and With R2 and R3 providing four 
carbon atoms. More preferably, R2 is hydrogen, methyl, ethyl, 
butyl, phenyl, 3-hydroxypropyl, l-methyl-2-pyrrolidinyl, 
bromo, forms a six membered ring With A1, A2 and R1 and 
with R1 and R2 providing four unsaturated carbon atoms, 
forms a phenyl group With A1, A2 and R1, forms a six mem 
bered ring With A2, A3 and R3 and With R2 and R3 providing 
four unsaturated carbon atoms, or forms a phenyl group With 
A2, A3 and R3 . 
In a compound of Formula (I), preferably R3 is hydrogen, 
alkyl, or forms a six membered ring With A2, A3 and R2 and 
With R2 and R3 providing four carbon atoms. More preferably, 
R3 is hydrogen, methyl, forms a six membered ring With A2, 
A3 and R2 and With R2 and R3 providing four unsaturated 
carbon atoms, or forms a phenyl group With A2, A3 and R2. 
In a compound of Formula (I), preferably R4 is hydrogen or 
alkyl. More preferably, R4 is hydrogen or methyl. 
In a compound of Formula (I), preferably R5 is hydrogen. 
In a compound of Formula (I), preferably Z1 is absent, or is 
alkyl, alkynyl, or alkoxy. More preferably, Z1 is absent, butyl, 
but-3 -ynyl, pentyl, pent-4-ynyl or 2-ethoxy. 
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In a compound of Formula (I), preferably Z2 is alkyl, aryle 
nyl or alkoxy. More preferably, Z2 is hexyl, octyl, dodecyl, 
tridecyl, para-phenylene, or 2-ethoxy. 
In a compound of Formula (I), preferably Z3 is alkyl, alky 
nyl, aryl or heterocyclic. More preferably Z3 is propyl, butyl, 
but- 1 -ynyl, hex-l -ynyl, phenyl, or 3 -pyridinyl. 
In a compound of Formula (I), preferably X is a halogen. 
More preferably, X is chloride, bromide or iodide. 
In one embodiment, the compound of Formula (I) is 
de?ned WhereinAl , A2, A3 , A4, andA5 are carbon; wherein R1 
is hydrogen, methyl, forms a six membered ring With A1, A2 
and R2 and with R1 and R2 providing four unsaturated carbon 
atoms, or forms a phenyl group With A1, A2 and R2; Wherein 
R2 is hydrogen, methyl, ethyl, butyl, phenyl, 3-hydroxypro 
pyl, l-methyl-2-pyrrolidinyl, bromo, forms a six membered 
8 
is hydrogen, methyl, forms a six membered ring With A1, A2 
and R2 and with R1 and R2 providing four unsaturated carbon 
atoms, or forms a phenyl group With A1, A2 and R2; Wherein 
R2 is hydrogen, methyl, ethyl, 3-hydroxypropyl, l-methyl-2 
pyrrolidinyl, bromo, forms a six membered ring With A1, A2 
and R1 and with R1 and R2 providing four unsaturated carbon 
atoms, forms a phenyl group With A1, A2 and R1, forms a six 
membered ring With A2, A3 and R3 and With R2 and R3 pro 
viding four unsaturated carbon atoms, or forms a phenyl 
group With A2, A3 and R3; Wherein R3 is hydrogen, methyl, 
forms a six membered ring WlIhAZ, A3 and R2 and With R2 and 
R3 providing four unsaturated carbon atoms, or forms a phe 
nyl group With A2, A3 and R2; Wherein R4 is hydrogen or 
methyl; Wherein R5 is hydrogen; wherein Z1 is absent, butyl, 15 
ring With A1, A2 and R1 and with R1 and R2 providing four but-3-ynyl, pent-4-ynyl or 2-ethoxy; Wherein Z2 is hexyl, 
unsaturated carbon atoms, forms a phenyl group With A1, A2 octyl, dodecyl, tridecyl, para-phenylene, or 2-ethoxy; 
and R1, forms a six membered ring With A2, A3 and R3 and Wherein Z3 is propyl, butyl, but-l-ynyl, hex-l-ynyl, phenyl, 
With R2 and R3 providing four unsaturated carbon atoms, or or 3-pyridinyl; and Wherein X is chloride, bromide or iodide. 
forms a phenyl group With A2, A3 and R3; Wherein R3 is 20 In another embodiment, the compound of Formula (I) is 
hydrogen, methyl, forms a six membered ring With A2, A3 and de?ned WhereinAl,A2,A3 , A4, and A5 are carbon; wherein R1 
R2 and With R2 and R3 providing four unsaturated carbon is hydrogen, methyl, or forms a phenyl group WlIhAl,A2 and 
atoms, or forms a phenyl group With A2, A3 and R2; Wherein R2; Wherein R2 is hydrogen, methyl, butyl, phenyl, l-methyl 
R4 is hydrogen or methyl; Wherein R5 is hydrogen; Wherein 2-pyrrolidinyl, forms a phenyl group With A1, A2 and R1, or 
Z1 is absent, butyl, but-3-ynyl, pentyl, pent-4-ynyl or 25 forms a phenyl group With A2, A3 and R3; Wherein R3 is 
2-ethoxy; Wherein Z2 is hexyl, octyl, dodecyl, tridecyl, para- hydrogen, methyl, or forms a phenyl group With A2, A3 and 
phenylene, or 2-ethoxy; Wherein Z3 is propyl, butyl, but-l- R2; Wherein R4 is hydrogen or methyl; Wherein R5 is hydro 
ynyl, hex-l-ynyl, phenyl, or 3-pyridinyl; and Wherein X is gen; wherein Z1 is pentyl or pent-4-ynyl; Wherein Z2 is para 
chloride, bromide or iodide. phenylene; Wherein Z3 is phenyl; and Wherein X is bromide. 
In another embodiment, the compound of Formula (I) is Exemplary compounds forthis application are presented in 
de?ned WhereinAl,A2,A3 ,A4, andA5 are carbon; wherein R1 Table 1. 
TABLE 1 
R3 
R4 R2 / | 
\@ 
H N R1 
21 X9 
I 2 
23/2 
ID # R1 R2 R3 R4 Z1 22 Z3 x 
GZ—S 65A H Me H H but—3 —ynyl p-phenyl phenyl bromide 
GZ—565B Me H H H but-3—ynyl p-phenyl phenyl bromide 
GZ—565C H H Me H but-3—ynyl p-phenyl phenyl bromide 
GZ—566A H Me H Me but-3—ynyl p-phenyl phenyl bromide 
GZ—566B H Me Me H but-3—ynyl p-phenyl phenyl bromide 
GZ—566C Me H Me H but-3—ynyl p-phenyl phenyl bromide 
GZ—567A phenyl With R2 phenyl with R1 H H but-3—ynyl p-phenyl phenyl bromide 
GZ—567B H phenyl With R3 phenyl With R2 H but-3—ynyl p-phenyl phenyl bromide 
GZ—567C H l—methyl—Z— H H but-3—ynyl p-phenyl phenyl bromide 
pyrrolidinyl 
GZ—S 68A H butyl H H but—3 —ynyl p-phenyl phenyl bromide 
GZ—568B H phenyl H H but-3—ynyl p-phenyl phenyl bromide 
GZ—568C H H H H but-3—ynyl p-phenyl phenyl bromide 
GZ—573A H Me H H butyl p-phenyl phenyl bromide 
GZ—573B Me H H H butyl p-phenyl phenyl bromide 
GZ—573C H H Me H butyl p-phenyl phenyl bromide 
GZ—574A H Me H Me butyl p-phenyl phenyl bromide 
GZ—574B H Me Me H butyl p-phenyl phenyl bromide 
GZ—574C Me H Me H butyl p-phenyl phenyl bromide 
GZ—575A phenyl With R2 phenyl with R1 H H butyl p-phenyl phenyl bromide 
GZ—575B H phenyl With R3 phenyl With R2 H butyl p-phenyl phenyl bromide 
GZ—575C H l—methyl—Z— H H butyl p-phenyl phenyl bromide 
pyrrolidinyl 
GZ—576A H butyl H H butyl p-phenyl phenyl bromide 
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phenyl)-pent-4-ynyl]-pyridinium bromide; 2,4-dimethyl-1 
[4- (4 -propyl -phenyl) -p ent-4 -ynyl] -pyridinium bromide; 
2-[4-(4-propyl-phenyl)-pent-4-ynyl]-5,6,7,8-tetrahydro-iso 
quinolinium bromide; 1-[5-(1,1'-biphenyl-4-yl)-pent-4 
ynyl] -3 -(1-methyl-2 -pyrrolidinyl)-pyridinium bromide; 
1-[5-(1,1'-biphenyl-4-yl)-pentyl]-3-(1-methyl-2-pyrrolidi 
nyl)-pyridinium bromide; 1-[2-(2-hexoxy-ethoxy)-ethyl]-3 
methyl -pyridinium chloride; 1-[2-(2 -hexoxy-ethoxy)-ethyl] - 
4-methyl-pyridinium chloride; 1-[2-(2-hexoxy-ethoxy) 
ethyl]-3,4-dimethyl-pyridinium chloride; 1-[2-(2-hexoxy 
ethoxy)-ethyl]-3,5-dimethyl-pyridinium chloride; 1-[2-(2 
hexoxy-ethoxy)-ethyl]-2-methyl-pyridinium chloride; 1-[2 
(2-hexoxy-ethoxy)-ethyl] -2,4-dimethyl-pyridinium 
chloride; 1-[2-(2-hexoxy-ethoxy)-ethyl] -5,6,7,8-tetrahydro 
quinolinium chloride; 2-[2-(2-hexoxy-ethoxy)-ethyl]-5,6,7, 
8-tetrahydro-isoquinolinium chloride; 1-[2-(2-hexoxy 
ethoxy)-ethyl]-3-methyl-pyridinium chloride; 1-[2-(2 
hexoxy-ethoxy)-ethyl]-3-methyl-pyridinium chloride; 
3 -methyl-1-[12-(3 -pyridinyl)-dodecyl] -pyridinium bromide; 
4-methyl-1-[12-(3 -pyridinyl)-dodecyl] -pyridinium bromide; 
3-bromo-1-[12-(3-pyridinyl)-dodecyl]-pyridinium bromide; 
3,4-dimethyl-1-[12-(3-pyridinyl)-dodecyl]-pyridinium bro 
mide; 3 ,5 -dimethyl-1-[12-(3 -pyridinyl) -dodecyl] -pyri 
dinium bromide; and 3-(1-methyl-2-pyrrolidinyl)-1-[12-(3 
pyridinyl) -dodecyl] -pyridinium bromide. 
The compounds of the present invention may contain one 
or more stereocenters. The invention includes all possible 
diastereomers and all enantiomeric forms as well as racemic 
mixtures. The compounds can be separated into substantially 
optically pure compounds. 
The compounds of the invention are nicotinic acetylcholi 
nereceptor agents. Thus, they may augment or inhibit[3 H] 
nicotine binding, [3H]MLA binding, evoke or inhibit neu 
rotransmitter release, and/or evoke or inhibit the ?ux of ions 
through the nicotinic receptor. 
In one embodiment, the present invention relates to a 
method for selectively modulating the function of a nicotinic 
acetylcholine receptor comprising administering to a mam 
malian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an agoinst or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutryic acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-ami 
nobutryic acid, or glutamate. 
In another embodiment, the present invention is directed to 
a method for preventing and/or treating a central nervous 
system associated disorder comprising administering to a 
mammalian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an agoinst or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
5 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
14 
nephrine, serotonin, gamma-aminobutryic acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-ami 
nobutryic acid, or glutamate. 
Central nervous system disorders Which may be treated 
according to the method of the present invention include 
Alzheimer’s disease, dementia, cognitive dysfunctions (in 
cluding disorders of attention, focus and concentration), 
attention de?cit disorders, affective disorders, extrapyrami 
dal motor function disorders, Parkinson’s disease, progres 
sive supramolecular palsy, Huntington’s disease, Gilles de la 
Tourette syndrome, tardive dyskinesia, neuroendocrine dis 
orders, dysregulation of food intake, disorders of nociception, 
pain, mood and emotional disorders, depression, panic anxi 
ety, psychosis, schizophrenia, or epilepsy. 
In yet another embodiment, the present invention is 
directed to a method for preventing and/ or treating sub stance 
use and/or abuse comprising administering to a mammalian 
subject in need thereof a therapeutically effective amount of a 
compound of Formula (I). In such a method, the compound of 
Formula (I) may selectively bind to one or more subtypes of 
nicotinic acetylcholine receptor. The compound of Formula 
(I) may act as an agoinst or partial agonist of nicotinic ace 
tylcholine receptor function. Hence the compound of For 
mula (I) may increase or prolong the release of a neurotrans 
mitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutryic acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-ami 
nobutryic acid, or glutamate. 
The conditions of substance use and/or abuse treated 
according to the method of the present invention include 
nicotine abuse (including use in smoking cessation therapy), 
nicotine intoxication, amphetamine abuse, methamphet 
amine abuse, cocaine abuse, or alcohol abuse. 
In another embodiment, the present invention is directed to 
a method for preventing and/ or treating gastrointestinal tract 
disorders comprising administering to a mammalian subject 
in need thereof a therapeutically effective amount of a com 
pound of Formula (I). In such a method, the compound of 
Formula (I) may selectively bind to one or more subtypes of 
nicotinic acetylcholine receptor. The compound of Formula 
(I) may act as an agoinst or partial agonist of nicotinic ace 
tylcholine receptor function. Hence the compound of For 
mula (I) may increase or prolong the release of a neurotrans 
mitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutryic acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-ami 
nobutryic acid, or glutamate. 
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Gastrointestinal disorders which may be treated according 
to the method of the present invention include irritable bowel 
syndrome, colitis, diarrhea, constipation, gastric acid secre 
tion or ulcers. 
The compounds of the present invention can be delivered 
directly or in pharmaceutical compositions along with suit 
able carriers or excipients, as is well known in the art. For 
example, a pharmaceutical composition of the invention may 
include a conventional additive, such as a stabilizer, buffer, 
salt, preservative, ?ller, ?avor enancer and the like, as known 
to those skilled in the art. Exemplary buffers include phos 
phates, carbonates, citrates and the like. Exemplary preserva 
tives include EDTA, EGTA, BHA, BHT and the like. 
An effective amount of such agents can readily be deter 
mined by routine experimentation, as can the most effective 
and convenient route of administration and the most appro 
priate formulation. Various formulations and drug delivery 
systems are available in the art. See, e. g., Gennaro, A. R., ed. 
(1995) Remington’s Pharmaceutical Sciences. 
Suitable routes of administration may, for example, 
include oral, rectal, transmucosal, nasal, or intestinal admin 
istration and parenteral delivery, including intramuscular, 
subcutaneous, intramedullary injections, as well as intrathe 
cal, direct intraventricular, intravenous, intraperitoneal, intra 
nasal, or intraocular injections. The agent or composition 
thereof may be administered in a local rather than a systemic 
manner. For example, a suitable agent can be delivered via 
injection or in a targeted drug delivery system, such as a depot 
or sustained release formulation. 
The pharmaceutical compositions of the present invention 
may be manufactured by any of the methods well-known in 
the art, such as by conventional mixing, dissolving, granulat 
ing, dragee-making, levigating, emulsifying, encapsulating, 
entrapping, or lyophilizing processes. As noted above, the 
compositions of the present invention can include one or 
more physiologically acceptable carriers such as excipients 
and auxiliaries that facilitate processing of active molecules 
into preparations for pharmaceutical use. 
Proper formulation is dependent upon the route of admin 
istration chosen. For injection, for example, the composition 
may be formulated in aqueous solutions, preferably in physi 
ologically compatible buffers such as Hanks’ solution, Ring 
er’ s solution, or physiological saline buffer. For transmucosal 
or nasal administration, penetrants appropriate to the barrier 
to be permeated are used in the formulation. Such penetrants 
are generally known in the art. In a preferred embodiment of 
the present invention, the present compounds are prepared in 
a formulation intended for oral administration. For oral 
administration, the compounds can be formulated readily by 
combining the active compounds with pharmaceutically 
acceptable carriers well known in the art. Such carriers enable 
the compounds of the invention to be formulated as tablets, 
pills, dragees, capsules, liquids, gels, syrups, slurries, suspen 
sions and the like, for oral ingestion by a subject. The com 
pounds may also be formulated in rectal compositions such as 
suppositories or retention enemas, e.g., containing conven 
tional suppository bases such as cocoa butter or other glyc 
erides. 
Pharmaceutical preparations for oral use canbe obtained as 
solid excipients, optionally grinding a resulting mixture, and 
processing the mixture of granules, after adding suitable aux 
iliaries, if desired, to obtain tablets or dragee cores. Suitable 
excipients are, in particular, ?llers such as sugars, including 
lactose, sucrose, mannitol, or sorbitol; cellulose preparations 
such as, for example, maize starch, wheat starch, rice starch, 
potato starch, gelatin, gum tragacanth, methyl cellulose, 
hydroxypropylmethyl-cellulose, sodium carboxymethylcel 
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lulose, and/or polyvinylpyrrolidone (PVP). If desired, disin 
tegrating agents may be added, such as the cross-linked poly 
vinyl pyrrolidone, agar, or alginic acid or a salt thereof such as 
sodium alginate. Also, wetting agents such as sodium dodecyl 
sulfate may be included. 
Dragee cores are provided with suitable coatings. For this 
purpose, concentrated sugar solutions may be used, which 
may optionally contain gum arabic, talc, polyvinyl pyrroli 
done, carbopol gel, polyethylene glycol, and/or titanium 
dioxide, lacquer solutions, and suitable organic solvents or 
solvent mixtures. Dyestuffs or pigments may be added to the 
tablets or dragee coatings for identi?cation or to characterize 
different combinations of active compound doses. 
Pharmaceutical preparations for oral administration 
include push-?t capsules made of gelatin, as well as soft, 
sealed capsules made of gelatin and a plasticizer, such as 
glycerol or sorbitol. The push-?t capsules can contain the 
active ingredients in admixture with ?ller such as lactose, 
binders such as starches, and/or lubricants such as talc or 
magnesium stearate and, optionally, stabilizers. In soft cap 
sules, the active compounds may be dissolved or suspended in 
suitable liquids, such as fatty oils, liquid paraf?n, or liquid 
polyethylene glycols. In addition, stabilizers may be added. 
All formulations for oral administration should be in dosages 
suitable for such administration. 
In one embodiment, the compounds of the present inven 
tion can be administered transdermally, such as through a skin 
patch, or topically. In one aspect, the transdermal or topical 
formulations of the present invention can additionally com 
prise one or multiple penetration enhancers or other effectors, 
including agents that enhance migration of the delivered com 
pound. Transderrnal or topical administration could be pre 
ferred, for example, in situations in which location speci?c 
delivery is desired. 
For administration by inhalation, the compounds for use 
according to the present invention are conveniently delivered 
in the form of an aerosol spray presentation from pressurized 
packs or a nebulizer, with the use of a suitable propellant, e. g., 
dichlorodi?uoromethane, trichloro?uoromethane, dichlo 
rotetra?uoroethane, carbon dioxide, or any other suitable gas. 
In the case of a pressurized aerosol, the appropriate dosage 
unit may be determined by providing a valve to deliver a 
metered amount. Capsules and cartridges of, for example, 
gelatin, for use in an inhaler or insuf?ator may be formulated. 
These typically contain a powder mix of the compound and a 
suitable powder base such as lactose or starch. 
Compositions formulated for parenteral administration by 
injection, e. g., by bolus injection or continuous infusion can 
be presented in unit dosage form, e.g., in ampoules or in 
multi-dose containers, with an added preservative. The com 
positions may take such forms as suspensions, solutions, or 
emulsions in oily or aqueous vehicles, and may contain for 
mulatory agents such as suspending, stabilizing and/or dis 
persing agents. Formulations for parenteral administration 
include aqueous solutions or other compositions in water 
soluble form. 
Suspensions of the active compounds may also be prepared 
as appropriate oily injection suspensions. Suitable lipophilic 
solvents or vehicles include fatty oils such as sesame oil and 
synthetic fatty acid esters, such as ethyl oleate or triglycer 
ides, or liposomes. Aqueous injection suspensions may con 
tain substances that increase the viscosity of the suspension, 
such as sodium carboxymethyl cellulose, sorbitol, or dextran. 
Optionally, the suspension may also contain suitable stabiliz 
ers or agents that increase the solubility of the compounds to 
allow for the preparation of highly concentrated solutions. 
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Alternatively, the active ingredient may be in powder form for 
constitution with a suitable vehicle, e.g., sterile pyrogen-free 
water, before use. 
As mentioned above, the compositions of the present 
invention may also be formulated as a depot preparation. 
Such long acting formulations may be administered by 
implantation (for example, subcutaneously or intramuscu 
larly) or by intramuscular injection. Thus, for example, the 
present compounds may be formulated with suitable poly 
meric or hydrophobic materials (for example as an emulsion 
in an acceptable oil) or ion exchange resins, or as sparingly 
soluble derivatives, for example, as a sparingly soluble salt. 
Suitable carriers for the hydrophobic molecules of the 
invention are well known in the art and include co-solvent 
systems comprising, for example, benzyl alcohol, a nonpolar 
surfactant, a water-miscible organic polymer, and an aqueous 
phase. The co-solvent system may be the VPD co-solvent 
system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v 
of the nonpolar surfactant polysorbate 80, and 65% w/v poly 
ethylene glycol 300, made up to volume in absolute ethanol. 
The VPD co-solvent system (V PD15W) consists of VPD 
diluted 1:1 with a 5% dextrose in water solution. This co 
solvent system is effective in dissolving hydrophobic com 
pounds and produces low toxicity upon systemic administra 
tion. Naturally, the proportions of a co-solvent system may be 
varied considerably without destroying its solubility and tox 
icity characteristics. Furthermore, the identity of the co-sol 
vent components may be varied. For example, other low 
toxicity nonpolar surfactants may be used instead of 
polysorbate 80, the fraction size of polyethylene glycol may 
be varied, other biocompatible polymers may replace poly 
ethylene glycol, e. g., polyvinyl pyrrolidone, and other sugars 
or polysaccharides may substitute for dextrose. 
Alternatively, other delivery systems for hydrophobic mol 
ecules may be employed. Liposomes and emulsions are well 
known examples of delivery vehicles or carriers for hydro 
phobic drugs. Liposomal delivery systems are discussed 
above in the context of gene-delivery systems. Certain 
organic solvents such as dimethylsulfoxide also may be 
employed, although usually at the cost of greater toxicity. 
Additionally, the compounds may be delivered using sus 
tained-release systems, such as semi-permeable matrices of 
solid hydrophobic polymers containing the effective amount 
of the composition to be administered. Various sustained 
release materials are established and available to those of skill 
in the art. Sustained-release capsules may, depending on their 
chemical nature, release the compounds for a few weeks up to 
over 100 days. Depending on the chemical nature and the 
biological stability of the therapeutic reagent, additional 
strategies for stabilization may be employed. 
For any composition used in the present methods of treat 
ment, a therapeutically effective dose can be estimated ini 
tially using a variety of techniques well known in the art. For 
example, in a cell culture assay, a dose can be formulated in 
animal models to achieve a circulating concentration range 
that includes the lC50 as determined in cell culture. Dosage 
ranges appropriate for human subjects can be determined, for 
example, using data obtained from cell culture assays and 
other animal studies. 
A therapeutically effective dose of an agent refers to that 
amount of the agent that results in amelioration of symptoms 
or a prolongation of survival in a subject. Toxicity and thera 
peutic ef?cacy of such molecules can be determined by stan 
dard pharmaceutical procedures in cell cultures or experi 
mental animals, e. g., by determining the LD50 (the dose lethal 
to 50% of the population) and the ED50 (the dose therapeuti 
cally effective in 50% of the population). The dose ratio of 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
18 
toxic to therapeutic effects is the therapeutic index, which can 
be expressed as the ratio LDSO/EDSO. Agents that exhibit high 
therapeutic indices are preferred. 
Dosages preferably fall within a range of circulating con 
centrations that includes the ED50 with little or no toxicity. 
Dosages may vary within this range depending upon the 
dosage form employed and the route of administration uti 
lized. The exact formulation, route of administration, and 
dosage should be chosen, according to methods known in the 
art, in view of the speci?cs of a subject’s condition. 
The amount of agent or composition administered will, of 
course, be dependent on a variety of factors, including the sex, 
age, and weight of the subject being treated, the severity of the 
af?iction, the manner of administration, and the judgment of 
the prescribing physician. 
The present compositions may, if desired, be presented in a 
pack or dispenser device containing one or more unit dosage 
forms containing the active ingredient. Such a pack or device 
may, for example, comprise metal or plastic foil, such as a 
blister pack. The pack or dispenser device may be accompa 
nied by instructions for administration. Compositions com 
prising a compound of the invention formulated in a compat 
ible pharmaceutical carrier may also be prepared, placed in an 
appropriate container, and labeled for treatment of an indi 
cated condition. 
These and other embodiments of the present invention will 
readily occur to those of ordinary skill in the art in view of the 
disclosure herein, and are speci?cally contemplated. 
EXAMPLES 
The invention is further understood by reference to the 
following examples, which are intended to be purely exem 
plary of the invention. The present invention is not limited in 
scope by the exempli?ed embodiments, which are intended as 
illustrations of single aspects of the invention only. Any meth 
ods that are functionally equivalent are within the scope of the 
invention. Various modi?cations of the invention in addition 
to those described herein will become apparent to those 
skilled in the art from the foregoing description. Such modi 
?cations fall within the scope of the appended claims. 
Example 1 
Synthesis of compound 
2-methyl- 1 -(8 -phenyl-octyl)-pyridinium bromide 
(8-Bromo-octyl)-benzene (1 mmol) was added to a solu 
tion of 2-picoline (3 mmol) in acetonitrile, and the solution 
mixture was re?uxed for 24 hours. The acetonitrile was 
removed in a vacuum, and the resulting residue was parti 
tioned between ether and water. The aqueous layer was 
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washed extensively with ether until no picoline was left in the 
aqueous layer. The resulting aqueous solution of the product 
was extracted with chloroform. The chloroform was removed 
to afford the product (70%). lHNMR (300 MHZ, CDCl3, 
ppm) 9.74 (d, 1H), 8.35 (m, 1H), 7.96 (m, 1H), 7.86 (d, 1H), 
7.15-7.25 (m, 4H), 4.92 (t, 2H), 2.95 (s, 3H), 1.88-1.98 (m, 
2H), 1.54-1.64 (m, 2H), 1.39-1.49 (m, 2H), 1.25-1.38 (br, 
6H). 
Example 2 
Synthesis of Compound 
3 -methyl- 1 - (8 -phenyl -octyl) -pyridinium bromide 
(8-Bromo-octyl)-benzene (1 mmol) was added to a solu 
tion of 3-picoline (3 mmol) in acetonitrile, and the solution 
re?uxed for 24 hours. The acetonitrile was removed in a 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no picoline was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the prod 
uct (76%). lHNMR (300 MHZ, CDCl3, ppm) 9.40 (s, 1H), 
9.22 (d, 1H), 8.02 (d, 1H), 7.96 (dd, 1H), 7.12-7.22 (dd, 4H), 
4.94 (t, 2H), 2.62 (s, 3H), 2.56 (t, 2H), 1.94-2.04 (m, 2H), 
1.50-1.60 (m, 2H), 1.20-1.40 (br, 8H). l3CNMR, 145.68, 
144.65, 142.87, 142.37, 139.79, 128.55, 128.40, 127.89, 
125.76, 62.20, 36.19, 32.29, 31.73, 29.53, 29.44, 29.33, 
26.40,19.11. 
Example 3 
Synthesis of Compound 
2,4-dimethyl-1 -(8 -phenyl-octyl)-pyridinium bromide 
Br / 
18—, 
ACN, 
re?ux 
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(8-Bromo-octyl)-benzene (1 mmol) was added to a solu 
tion of 2,4-lutidine (3 mmol) in acetonitrile, and the solution 
re?uxed for 24 hours. The acetonitrile was removed in a 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 2,4-lutidine was left in the aqueous layer. 
The resulting aqueous solution of the product was extracted 
with chloroform. The chloroform was removed to afford the 
product (70%). lHNMR (300 MHZ, CDCl3, ppm), 9.50 (d, 
1H), 7.70 (d, 1H), 7.60 (s, 1H), 7.10-7.30 (dd, 1H), 4.78 (t, 
2H), 2.84 (s, 3H), 2.54-2.60 (m, 5H), 1.80-1.92 (m, 2H), 
1.50-1.60 (br, 2H), 1.20-1.45 (br, 6H). 
Example 4 
Synthesis of Compound 
4-methyl- 1 -(8 -phenyl-octyl)-pyridinium bromide 
| \ 
Br / 
N 
ACN, UWW re?ux 
/ 
G) 
N \ 
Bre 
(8-Bromo-octyl)-benzene (1 mmol) was added to a solu 
tion of 4-picoline (3 mmol) in acetonitrile, and the solution 
was re?uxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no picoline was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the prod 
uct (78%). lHNMR (300 MHZ, CDCl3, ppm) 9.26 (d, 2H), 
7.84 (d, 2H), 7.14-7.28 (dd, 4H), 4.90 (t, 2H), 2.62 (s, 3H), 
2.56 (t, 2H), 1.92-2.02 (m, 2H), 1.50-1.60 (m, 2H), 1.20-1.40 
(br, 8H). l3CNMR, 158.92, 144.28, 142.86, 128.95, 128.56, 
128.40, 125.76, 61.61, 36.19, 32.15, 31.71, 29.53, 29.42, 
29.31, 26.37, 22.63. 
Example 5 
Synthesis of Compound 
1-dodec-7-ynyl-2-methyl-pyridinium iodide 
I / 
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/ | 
G) 
N \ 
¢ @ 
12-Chloro-dodec-5-yne (1 mmol) was mixed with potas 
sium iodide (3 mmol) and 2-picoline (3 mmol) in butanone. 
room temperature. The butanone was removed in a vacuum, 
and the resulting residue was partitioned between water and 
ethyl ether. The aqueous layer was washed extensively with 
ether until no 2-picoline was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the prod 
uct (85%). lHNMR (300 MHZ, CDCl3, ppm) 9.62 (d, 1H), 
8.39 (dd, 1H), 7.99 (m, 1H), 7.91 (d, 1H), 4.88 (t, 2H), 2.97 (s, 
3H), 2.12-2.20 m, 4H), 1.90-2.00 (m, 2H), 1.32-1.58 (m, 8H), 
0.88 (t, 3H). 
Example 6 
Synthesis of Compound 
1-dodec-7-ynyl-3 -methyl-pyridinium iodide 
\ 
I / 
N 
% 
12-Chloro-dodec-5-yne (1 mmol) was mixed with potas 
sium iodide (3 mmol) and 3-picoline (3 mmol) in butanone. 
The mixture was re?uxed for 3 days and cooled to room 
temperature, ?ltrated. The butanone was removed in a 
vacuum, and the resulting residue was partitioned between 
water and ethyl ether. The aqueous layer was washed exten 
sively with ether until no 3-picoline was left in the aqueous 
layer. The resulting aqueous solution of the product was 
extracted with chloroform. The chloroform was removed to 
afford the product (82%). lHNMR (300 MHZ, CDCl3, ppm) 
9.36 (s, 1H), 9.18 (d, 1H), 8.24 (d, 1H), 8.00 (dd, 1H), 4.92 (t, 
2H), 2.62 (s, 3H), 1.95-2.18 (m, 6H), 1.15-1.25 (br, 10H), 
0.90 (t, 3H); l3CNMR, 145.51, 144.12, 144.78, 139.46, 
127.56, 80.44, 79.42, 61.75, 31.72, 31.16, 28.65, 28.04, 
25.52, 21.92, 18.75, 18.55, 18.40, 13.63. 
Example 7 
Synthesis of compound 
1-dodec-7-ynyl-4-methyl-pyridinium iodide 
| \ 
Cl / 
4> W KI/Butanonc, 
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-continued 
12-Chloro-dodec-5-yne (1 mmol) was mixed with potas 
sium iodide (3 mmol) and 4-picoline (3 mmol) in butanone. 
The mixture was re?uxed for 3 days and cooled to room 
temperature, ?ltrated. The butanone was removed in a 
vacuum, and the resulting residue was partitioned between 
water and ethyl ether. The aqueous layer was washed exten 
sively with ether until no 4-picoline was left in the aqueous 
layer. The resulting aqueous solution of the product was 
extracted with chloroform. The chloroform was removed to 
afford the product (87%). lHNMR (300 MHZ, CDCl3, ppm), 
9.28 (d, 2H), 7.92 (d, 2H), 4.92 (t, 2H), 2.68 (s, 3H), 1.96-2.18 
(m, 6H), 1.32-1.50 (br, 10H), 0.88 (t, 3H). 
Example 8 
Synthesis of Compound 
1-dodec -7 -ynyl-2,4-dimethyl-pyridinium iodide 
| \ 
Cl N/ 
W KI/Butanonc, 
re?ux 
/ 
N6 | 
WI; 
12-Chloro-dodec-5-yne (1 mmol) was mixed with potas 
sium iodide (3 mmol) and 2,4-lutidine (3 mmol) in butanone. 
The mixture was re?uxed for 3 days and cooled to room 
temperature, ?ltrated. The butanone was removed in a 
vacuum, and the resulting residue was partitioned between 
water and ethyl ether. The aqueous layer was washed exten 
sively with ether until no 2,4-lutidine was left in the aqueous 
layer. The resulting aqueous solution of the product was 
extracted with chloroform. The chloroform was removed to 
afford the product (84%). lHNMR (300 MHZ, CDCl3, ppm), 
9.40 (d, 1H), 7.75 (d, 1H), 7.66 (s, 1H), 4.78 (t, 3H), 2.88 (s, 
3H), 2.60 (s, 3H), 2.05-2.15 (br, 4H), 1.80-2.00 (br, 2H), 
1.30-1.50 (br, 10H), 0.86 (t, 3H); l3CNMR, 156.73, 153.05, 
145.84, 136.61, 127.27, 80.86, 79.85, 58.12, 31.54, 30.94, 
39.09, 26.17, 22.39, 22.30, 21.03, 18.96, 18.79, 14.02. 
Example 9 
Synthesis of Compound 
1 -dodec -7 -ynyl-3, 5-dimethyl-pyridinium iodide 
| \ 
Cl N/ / W KI/Butanone, 
re?ux 
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12-Chloro-dodec-5-yne (1 mmol) was mixed with potas 
sium iodide (3 mmol) and 3,5-lutidine (3 mmol) in butanone. 
The mixture was re?uxed for 3 days and cooled to room 
temperature, ?ltrated. The butanone was removed in vacuum, 
and the resulting residue was partitioned between water and 
ethyl ether. The aqueous layer was washed extensively with 
ether until no 3,5-lutidine was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the prod 
uct (78%). lHNMR (300 MHZ, CDCl3, ppm), 9.06 (s, 2H), 
8.00 (s, 1H), 4.86 (t, 3H), 2.48 (s, 3H), 1.98-2.16 (m, 6H), 
1.32-1.48 (br, 10H), 0.88 (t, 3H); l3CNMR, 146.12, 141.38, 
138.64, 80.43, 79.53, 61.46, 31.70, 31.17, 28.68, 28.07, 
25.55, 21.92, 18.57, 18.42, 13.63. 
Example 10 
Synthesis of Compound 
1-dodec -7 -ynyl-3,4-dimethyl-pyridinium iodide 
Cl / 
N—, W KUButanonc, 
12-Chloro-dodec-5-yne (1 mmol) was mixed with Sodium 
iodide (3 mmol) and 3,4-lutidine (3 mmol) in butanone. The 
mixture was re?uxed for 3 days and cooled to room tempera 
ture, ?ltrated. The butanone was removed in vacuum, and the 
resulting residue was partitioned between water and ethyl 
ether. The aqueous layer was washed extensively with ether 
until no 3,4-lutidine was left in the aqueous layer. The result 
ing aqueous solution of the product was extracted with chlo 
roform. The chloroform was removed to afford the product 
(72%). lHNMR, (300 MHZ, CDCl3, ppm, ppm), 9.22 (s, 1H), 
9.04 (d, 1H), 7.80 (d, 1H), 4.84 (t, 3H), 2.52 (s, 3H), 2.50 (s, 
3H), 1.92-2.14 (m, 6H), 1.28-1.45 (m, 10H), 0.84 (t, 3H). 
l3CNMR, 157.84, 143.39, 141.81, 138.53, 128.72, 80.80, 
79.90, 61.23, 32.03, 31.54, 29.08, 28.48, 25.91, 22.30, 20.78, 
18.96, 18.79, 17.44, 14.02. 
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Example 11 
Synthesis of 1-dodec-9-ynyl-2-methyl-pyridinium 
bromide 
| \ 
/ 
Br N 
H3C ACN, re?ux 
—_ N (9 
H30 \ / 
Bre 
12-Bromo-dodec-3-yne (1 mmol) was added to a solution 
of 2-picoline (3 mmol) in acetonitrile, and the solution was 
re?uxed for 24 hours. The acetonitrile was removed in 
vacuum, and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 2-picoline was left in the aqueous layer. 
The resulting aqueous solution of the product was extracted 
with chloroform. The chloroform was removed to afford the 
product (70%). lHNMR (300 MHZ, CDCl3, ppm), 9.68 (d, 
1H), 8.28 (m, 1H), 7.96 (m, 1H), 7.84 (d, 1H), 4.94 (t, 2H), 
2.98 (s, 3H), 2.05-2.20 (m, 4H), 1.88-2.00 (m, 2H), 1.20-1.60 
(br, 10H), 1.10 (t, 3H). 
Example 12 
Synthesis of Compound 
1-dodec-9-ynyl-3-methyl-pyridinium bromide 
\ 
Br I N/ 
W ACN, 
re?ux 
/ 
N@\ | 
12-Bromo-dodec-3-yne (1 mmol) was added to a solution 
of 3-picoline (3 mmol) in acetonitrile, and the solution was 
re?uxed for 24 hours. The acetonitrile was removed in a 
vacuum, and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no picoline was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the prod 
uct (70%). lHNMR (300 MHZ, CDCl3, ppm), 9.42 (s, 1H), 
9.24 (d, 1H), 8.24 (d, 1H), 8.00 (dd, 1H), 4.95 (t, 2H), 2.62 (s, 
3H), 1.95-2.2 (m, 6H), 1.23-1.45 (br, 10H), 1.1 (t, 3H); 
l3CNMR, 145.29, 144.24, 141.98, 139.42, 127.51, 81.57, 
79.26, 61.83, 31.90, 28.95, 28.92, 28.82, 28.62, 26.02, 18.72, 
18.63, 14.38, 12.40. 
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Example 13 
Synthesis of Compound 
1-dodec-9-ynyl-4-methyl-pyridinium bromide 
I \ 
Br N/ 
W AEN, 
/ 
Ni | We
12-Bromo-dodec-3-yne (1 mmol) was added to a solution 
of 4-picoline (3 mmol) in acetonitrile, and the solution was 
re?uxed for 24 hours. The acetonitrile was removed in a 
vacuum, and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no picoline was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the prod 
uct (82%). lHNMR (300 MHZ, CDCl3, ppm), 9.24 (d, 2H), 
7.86 (d, 2H), 4.90 (t, 2H), 2.64 (s, 3H), 1.95-2.16 (m, 6H), 
1.26-1.34 (br, 10H), 0.88 (t, 3H). 
Example 14 
Synthesis of 
1 - [4 -(4-butyl-phenyl)-butyl] -2-methyl -pyridinium 
bromide 
/ 
N MGM/Br 
1-(4-Bromo-butyl)-4-butyl-benZene (1 mmol) was added 
to a solution of 2-picoline (3 mmol) in acetonitrile, and the 
solution was re?uxed for 24 hours. The acetonitrile was 
removed in a vacuum, and the resulting residue was parti 
tioned between ether and water. The aqueous layer was 
washed extensively with ether until no 2-picoline was left in 
the aqueous layer. The resulting aqueous solution of the prod 
uct was extracted with chloroform. The chloroform was 
removed to afford the product (74%). lHNMR (300 MHZ, 
CDCl3, ppm), 9.69 (d, 1:6.6, 1H), 8.25-8.30 (m, 1H), 7.90 
7.95 (m, 1H), 7.77 (d, 1:7.8, 1H), 7.04-7.10 (m, 4H), 4.92 (t, 
7.5, 2H), 2.84 (s, 3H), 2.66 (t, 1:7.2, 2H), 2.56 (t, 1:7.5, 2H), 
26 
1.89-1.98 (m, 2H), 1.78-1.86 (m, 2H), 1.51-1.59 (m, 2H), 
1.27-1.37 (m, 2H), 0.91 (1, 1:7.2, 3H). 
Example 15 
Synthesis of Compound 
1-[4-(4 -butyl-phenyl)-butyl]-3-methyl-pyridinium 
bromide 
10 
\ 
Br I 
/ 
15 \A/Q/W N ACN, re?ux 
/ I 
(’3 
N 
20 \ 
6 
Br 
25 1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added 
to a solution of 3-picoline (3 mmol) in acetonitrile and the 
solution re?uxed for 24 hours. The acetonitrile was removed 
in vacuum, and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no picoline was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the prod 
uct (75%). lHNMR (300 MHZ, CDCl3, ppm), 9.32 (s, 1H), 
9.2 (d, 1:5.1, 1H), 8.16 (d, 1:51, 7.91 (m, 1H), 7.07 (d, 1:8.4, 
2H), 7.02 (d, 1:8.4, 2H), 4.96 (t, 1:7.2, 2H), 2.52-2.64 (m, 
7H), 2.00-2.06 (m, 2H), 1.60-1.70 (m, 2H), 1.60-1.60 (m, 
2H), 1.29-1.36 (m, 2H), 0.90 (t, 1:7.2, 3H); l3CNMR, 
145.62, 144.71, 142.37, 140.84, 139.73, 138.32, 128.66, 
128.48, 127.78, 61.82, 35.54, 34.95, 34.05, 31.71, 27.93, 
22.72, 19.07, 14.33. 
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35 
40 
Example 16 
Synthesis of Compound 
45 1 - [4 -(4 -butyl -phenyl)-butyl] -4-methyl -pyridinium 
bromide 
50 
\ 
Br I 
/ 
N 
55 ACN, 
re?ux 
/ I 
G) 
N \ 
60 9 
Br 
1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added 
65 to a solution of 4-picoline (3 mmol) in acetonitrile, and the 
solution was re?uxed for 24 hours. The acetonitrile was 
removed in a vacuum, and the resulting residue was parti 
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tioned between ether and water. The aqueous layer was 
washed extensively with ether until no picoline was left in the 
aqueous layer. The resulting aqueous solution of the product 
was extracted with chloroform. The chloroform was removed 
to afford the product (72%). lHNMR (300 MHZ, CDCl3, 
ppm), 9.22 (d, 1:6.6, 2H), 7.79 (d, 1:6.6, 2H), 7.05 (d, 1:8.4, 
2H), 7.02 (d, 1:8.4, 2H), 4.90 (t, 1:7.5, 3H), 2.51-2.63 (m, 
7H), 1.96-2.06 (m, 2H), 1.58-1.68 (m, 2H), 1.51-1.61 (m, 
2H), 1.31-1.37 (m, 2H), 0.89 (t, 1:7.2, 3H); l3CNMR, 
158.91, 144.31, 140.83, 138.30, 128.92, 128.66, 128.45, 
61.26, 35.54, 34.95, 34.04, 31.61, 27.95, 22.73, 22.57, 14.33. 
Example 17 
Synthesis of 2-[4-(4-butyl-phenyl)-butyl]-5,6,7,8 
tetrahydro-isoquinolinium bromide 
/ 
1-(4-Bromo-butyl)-4-butyl-benZene (1 mmol) was added 
to a solution of tetrahydroisoquinoline (2 mmol) in acetoni 
trile, and the solution was re?uxed for 24 hours. The aceto 
nitrile was removed in vacuum, and the resulting residue was 
partitioned between ether and water. The aqueous layer was 
washed extensively with ether until no tetrahydroisoquino 
line was left in the aqueous layer. The resulting aqueous 
solution of the product was extracted with chloroform. The 
chloroform was removed to afford the product (72%). 
lHNMR (300 MHZ, CDCl3, ppm), 9.12 (s, 1H), 8.85 (d, 
1:6.0, 1H), 7.61 (d, 1:6.0, 1H), 7.02-7.08 (m, 4H), 4.83 (t, 
7.5, 3H), 2.92-2.94 (m, 4H), 2.61 (t, 1:7.5, 2H), 2.54 (t, 1:7.5, 
2H), 1.90-2.04 (m, 2H), 1.80-1.90 (m, 4H), 1.62-1.69 (m, 
2H), 1.53-1.62 (m, 2H), 1.29-1.37 (m, 2H), 0.90 (t, 1:7.2, 
3H). 13CNMR, 157.94, 144.18, 140.82, 140.64. 138.96, 
138.37, 128.65, 128.48, 127.99, 61.16, 35.54, 34.99, 34.05, 
31.56, 29.92, 27.98, 26.69, 22.74, 21.37, 14.33. 
Example 18 
Synthesis of 1-[4-(4-butyl-phenyl)-butyl]-3-(3 -hy 
droxy-propyl) -pyridinium bromide 
/ OH 
Br 
OH 
1-(4-Bromo-butyl)-4-butyl-benZene (1 mmol) was added 
to a solution of hydroxypropanylpyridine (2 mmol) in aceto 
nitrile, and the solution was re?uxed for 24 hours. The aceto 
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nitrile was removed in a vacuum, and the resulting residue 
was partitioned between ether and water. The aqueous layer 
was washed extensively with ether until no hydroxypropa 
nylpyridine was left in the aqueous layer. The resulting aque 
ous solution of the product was extracted with chloroform. 
The chloroform was removed to afford the product (65%). 
lHNMR (300 MHZ, CDCl3, ppm), 9.41 (s, 1H), 8.85 (d, 
1:6.3, 1H), 8.26 (d, 1:8.1, 1H), 7.89 (dd, 1:63, 1:81, 1H), 
7.02-7.07 (m, 4H), 4.90 (t, 1:7.5, 2H), 3.59 (t, 1:5.4, 2H), 
3.00 (t, 1:6.9, 2H), 2.62 (t, 1:7.2, 2H), 2.55 (t, 1:7.8, 2H), 
1.95-2.05 (m, 4H), 1.57-1.69 (m, 2H), 1.50-1.60 (m, 2H), 
1.29-1.37 (m, 2H), 0.90 (t, 1:7.2, 3H). 
Example 19 
Synthesis of Compound 1-[4-(4-butyl-phenyl)-bu 
tyl] -2,4-dimethyl-pyridinium bromide 
/ 
1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added 
to a solution of 2,4-lutidine (3 mmol) in acetonitrile, and the 
solution was re?uxed for 24 hours. The acetonitrile was 
removed in a vacuum, and the resulting residue was parti 
tioned between ether and water. The aqueous layer was 
washed extensively with ether until no lutidine left in the 
aqueous layer. The resulting aqueous solution of the product 
was extracted with chloroform. The chloroform was removed 
to afford the product (79%). lHNMR (300 MHZ, CDCl3, 
ppm), 9.51 (d, 1:6.2, 1H), 7.67 (d, 1:6.2, 1H), 7.54 (s, 1H), 
7.05-7.07 (m, 4H), 4.83 (t, 1:7.2, 2H), 2.77 (s, 3H), 2.64 (t, 
1:7.2, 2H), 2.52-2.58 (m, 5H), 1.87-1.92 (m, 2H), 1.76-1.82 
(m, 2H), 1.50-1.58 (m, 2H), 1.29-1.37 (m, 2H), 0.91 (t, 1:7.8, 
3H). 
Example 20 
Synthesis of 1-[4-(4-butyl-phenyl)-butyl]-3,4-dim 
ethyl-pyridinium bromide 
/ | 
N \ 
ACN, re?ux N—legr 
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1-(4-Bromo-butyl)-4-butyl-benZene (1 mmol) was added 
to a solution of 3,4-lutidine (3 mmol) in acetonitrile, and the 
solution was re?uxed for 24 hours. The acetonitrile was 
removed in a vacuum, and the resulting residue was parti 
tioned between ether and water. The aqueous layer was 
washed extensively with ether until no lutidine left in the 
aqueous layer. The resulting aqueous solution of the product 
was extracted with chloroform. The chloroform was removed 
to afford the product (79%). lHNMR (300 MHZ, CDCl3, 
ppm), 9.20 (s, 1H), 9.03 (d, 1:6.3, 1H), 7.72 (d, 1:6.3, 1H), 
7.00-7.07 (m, 4H), 4.87 (t, 1:7.5, 2H), 2.60 (t, 1:7.8, 2H), 
2.54 (t, 1:7.8, 2H), 2.49 (s, 3H), 2.46 (s, 3H), 1.99-2.04 (m, 
2H), 1.50-1.66 (m, 4H), 1.28-1.36 (m, 2H), 0.90 (t, 1:7.5, 
3H). l3CNMR 157.60, 143.56, 141.92, 140.78, 138.40, 
128.63, 128.57, 128.47, 61.00, 35.54, 34.98, 34.04, 31.59, 
27.96, 22.73, 20.66, 17.36, 14.31. 
Example 21 
Synthesis of 1-[4-(4-butyl-phenyl)-butyl] -3,5-dim 
ethyl-pyridinium bromide 
/ 
MQMBI 
1-(4-Bromo-butyl)-4-butyl-benZene (1 mmol) was added 
to a solution of 3,5-lutidine (3 mmol) in acetonitrile, and the 
solution was re?uxed for 24 hours. The acetonitrile was 
removed in a vacuum, and the resulting residue was parti 
tioned between ether and water. The aqueous layer was 
washed extensively with ether until no lutidine was left in the 
aqueous layer. The resulting aqueous solution of the product 
was extracted with chloroform. The chloroform was removed 
to afford the product (81%). lHNMR (300 MHZ, CDCl3, 
ppm), 9.11 (s, 2H), 7.92 (s, 1H), 7.00-7.06 (m, 4H), 4.88 (t, 
1:7.5, 2H), 2.51-2.62 (m, 7H), 1.99-2.05 (m, 2H), 1.49-1.66 
(m, 4H), 1.28-1.35 (m, 2H), 0.89 (t, 1:7.2, 3H). l3CNMR, 
146.17, 141.96, 140.81, 138.91, 138.40, 128.63, 128.48, 
61.60, 35.54, 34.98, 34.05, 31.68, 27.95, 22.72, 18.88, 14.31. 
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Example 22 
Synthesis of Compound 1-[4-(4-butyl-phenyl)-but-3 
ynyl] -3-methyl-pyridinium bromide 
\\ 
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
added to a solution of 3-picoline (3 mmol) in acetonitrile, and 
the solution was re?uxed for 24 hours. The acetonitrile was 
removed in a vacuum, and the resulting residue was parti 
tioned between ether and water. The aqueous layer was 
washed extensively with ether until no picoline was left in the 
aqueous layer. The resulting aqueous solution of the product 
was extracted with chloroform. The chloroform was removed 
to afford the product (77%). lHNMR R (300 MHZ, CDCl3, 
ppm), 9.48 (s, 1H), 9.33 (d, 1:6.6, 1H), 8.24 (d, 1:7.2, 1H), 
7.93 (dd, 1:66, 1:72, 1H), 7.16 (d, 1:8.2, 2H), 7.06 (d, 
1:8.2, 2H), 5.21 (t, 1:6.0, 2H), 3.26 (t, 1:6.0, 2H), 2.59 (s, 
3H), 2.56 (t, 2H), 1.49-1.59 (m 2H), 1.25-1.37 (m, 2H), 0.9 (t, 
1:7.2, 3H); l3CNMR, 145.70, 144.78, 143.64, 142.26, 
138.98,131.15,128.32, 126.94, 118.92, 85.84, 82.45, 59.90, 
35.45, 33.28, 22.81. 22.24, 18.71, 13.89. 
Example 23 
Synthesis of Compound 1-[4-(4-butyl-phenyl)-but-3 
ynyl] -4-methyl-pyridinium bromide 
Br 
/ 
\\ 
Bre 
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1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
added to a solution of 4-picoline (3 mmol) in acetonitrile, and 
the solution was re?uxed for 24 hours. The acetonitrile was 
removed in vacuum, and the resulting residue was partitioned 
between ether and water. The aqueous layer was washed 
extensively with ether until no picoline was left in the aqueous 
layer. The resulting aqueous solution of the product was 
extracted with chloroform. The chloroform was removed to 
afford the product (67%). lHNMR (300 MHZ, CDCl3, ppm), 
9.40 (d, 1:6.9, 1H), 7.80 (d, 1H), 7.17 (d, 1:7.8, 2H), 7.06 (d, 
1:7.8, 2H), 5.2 (t, 2H), 3.23 (t, 2H), 2.65 (s, 3H), 2.56 (t, 
1:7.8, 2H), 1.49-1.57 (m, 2H), 1.27-1.35 (m, 2H), 0.90 (t, 
1:7.5, 3H). 
Example 24 
Synthesis of 1-[4-(4-butyl-phenyl)-but-3-ynyl]-3 
ethyl-pyridinium bromide 
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
added to a solution of 3-ethylpyridine (3 mmol) in acetoni 
trile, and the solution was re?uxed for 24 hours. The aceto 
nitrile was removed in vacuum, and the resulting residue was 
partitioned between ether and water. The aqueous layer was 
washed extensively with ether until no ethylpyridine was left 
in the aqueous layer. The resulting aqueous solution of the 
product was extracted with chloroform. The chloroform was 
removed to afford the product (67%). lHNMR (300 MHZ, 
CDCl3, ppm), 9.43 (d, 1:6.0, 1H), 9.41 (s, 1H), 8.25 (d, 1:8.1, 
1H), 7.96 (dd, 1:60, 1:81, 1H), 7.15 (d, 1:8.1, 2H), 7.06, d, 
1:8.1, 2H), 5.26 (t, 1:6.0, 2H), 3.26 (t, 1:6.0, 2H), 2.90 (q, 
1:7.5, 2H), 2.56 (t, 1:8.1, 2H), 1.49-1.59 (m, 2H), 1.27-1.37 
(m, 5H), 0.90 (t, 1:7.2, 3H); l3CNMR, 144.65, 144.46, 
144.14, 143.65, 142.45, 131.14, 128.30, 127.12, 118.87, 
85.88, 82.45, 59.99, 35.45, 33.27, 26.01, 22.85, 22.21, 14.26, 
13.88. 
Example 25 
Synthesis of 2-[4-(4-butyl-phenyl)-but-3 -ynyl]-5,6,7, 
8-tetrahydro -isoquinolinium bromide 
/ Br I 
% 
5 
45 
55 
60 
65 
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1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
added to a solution of tetrahyroisoquinoline (2 mmol) in 
acetonitrile, and the solution was re?uxed for 24 hours. The 
acetonitrile was removed in a vacuum, and the resulting resi 
due was partitioned between ether and water. The aqueous 
layer was washed extensively with ether until no tetrahyroiso 
quinoline was left in the aqueous layer. The resulting aqueous 
solution of the product was extracted with chloroform. The 
chloroform was removed to afford the product (68%). 
lHNMR (300 MHZ, CDCl3, ppm), 9.30 (s, 1H), 9.04 (d, 
1:6.3, 2H), 7.62 (d, 1:6.3, 1H), 7.18 (d, 1:8.4, 2H), 7.06 (d, 
1:8.4, 2H), 5.10 (t, 1:60, 3.21 (t, 1:6.0, 2H), 2.94-2.96 (m, 
2H), 2.56 (t, 1:8.1, 2H), 1.81-1.87 (m, 2H), 1.49-1.56 (m, 
2H), 1.27-1.34 (m, 2H), 0.89 (t, 1:7.2, 3H); l3CNMR, 
158.51, 144.59, 143.95, 140.93, 138.61, 131.55, 128.71, 
127.57, 119.46, 85.97, 83.23, 59.58, 35.86, 33.69, 31.01, 
26.70, 23.12, 22.63, 21.37, 14.28. 
Example 26 
Synthesis of 1-[4-(4-butyl-phenyl)-but-3 -ynyl]-3,4 
dimethyl-pyridinium bromide 
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
added to a solution of 3-hydroypropanylpyridine (2 mmol) in 
acetonitrile, and the solution was re?uxed for 24 hours. The 
acetonitrile was removed in a vacuum, and the resulting resi 
due was partitioned between ether and water. The aqueous 
layer was washed extensively with ether until no hydroypro 
panylpyridine was left in the aqueous layer. The resulting 
aqueous solution of the product was extracted with chloro 
form. The chloroform was removed to afford the product 
(60%). lHNMR (300 MHZ, CDCl3, ppm), 9.39 (s, 1H), 9.13 
(d, 1:6.3, 1H), 7.70 (d, 1:6.3, 1H), 7.17 (d, 1:8.1, 2H), 7.07 
(d, 1:8.1, 2H), 5.13 (t, 1:6.0, 2H), 3.23 (t, 1:6.0, 2H), 2.57 (t, 
1:7.8, 2H), 2.53 (s, 3H), 2.48 (s, 3H), 1.50-1.58 (m, 2H), 
1.28-1.37 (m, 2H), 0.90 (t, 1:7.2, 3H); l3CNMR, 158.19, 
143.98, 138.11, 131.53, 128.69, 128.05, 119.45, 83.11, 
59.60, 35.84, 33.64, 23.12, 22.62, 20.77, 17.35, 14.23. 
US 8,846,937 B2 
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Example 27 -continued 
Synthesis of 1-[4-(4-butyl-phenyl)-but-3-ynyl]-3,5- \ OH 
dimethyl-pyridinium bromide I 
5 N—QIi/M’a / 
B19 
\ 1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
I 10 added to a solution of 3-hydroypropanylpyridine (2 mmol) in 
B N / acetonitrile, and the solution was re?uxed for 24 hours. The 
— —> . ~ ~ ~ ~ 
I ACN, r??uX aceton1tr1le was removed 1n vacuum, and the result1ng residue 
was partitioned between ether and water. The aqueous layer 
15 was washed extensively with ether until no hydroypropa 
l \ nylpyridine was left in the aqueous layer. The resulting aque 
_— N® / 
B16 
ous solution of the product was extracted with chloroform. 
The chloroform was removed to afford the product (60%). 
20 lHNMR (300 MHZ, CDCl3, ppm), 9.46 (s, 1H), 9.04 (d, 
1:6.0, 1H), 8.33 (d, 1:8.1, 1H), 7.92 (dd, 1:60, 1:81, 1H), 
7.16 (d, 1:8.4, 2H), 7.04 (d, 1:8.1, 2H), 5.12 (t, 1:6.6, 2H), 
1'(4'Br°m°'bm'1'Yny1)'4'bmy1'benzene (1 mmol) was 3.57 (t 6.0 2H) 3.22 (t 1:6.0 2H) 2.98 (t 1:7.2 2H) 2.54 
added to a solution of 3,5-lutidine (2 mmol) in acetonitrile, (t 1:7’5 33) 1’94 (p 60 2H), 1 47,4 570,11 2H), 1 2611 34 
and the solution was re?uxed for 24 hours. The acetonitrile 25 ’ 2H’ 0 8’9 ' t 1:7 ’ 3H ’_ i3CN'MR 1’45 5’4 '144 '99 
was removed in a vacuum, and the resulting residue was 62 )’14i 83( ’1312'0’ 128x32 126 94" 11's 9’5 85'65’ 
partitioned between ether and water. The aqueous layer was 
washed extensively with ether until no lutidine was left in the 82-43, 59-92, 59-78, 58-26, 35-44, 3328, 3233, 2924, 2258, 
aqueous layer. The resulting aqueous solution of the product 22.23, 18.39, 13.88. 
was extracted with chloroform. The chloroform was removed 30 
to afford the product (80%). lHNMR (300 MHZ, coc13, Example 29 
ppm), 9.39 (s, 1H), 9.13 (d, 1:6.3, 1H), 7.70 (d, 1:6.3, 1H), 
7.17 (d, 1:8.1, 2H), 7.07 (d, 1:8.1, 2H), 5.13 (t, 1:6.0, 2H), Synthesis ofcompound 
3.23 (t, 1:6.0, 2H), 2.57 (t, 1:7.8, 2H), 2.53 (s, 3H), 2.48 (s, 3-methyl-1-(13-pyridin-3-yl-tridecyl)-pyridinium 
3H), 1.50-1.58 (m, 2H), 1.28-1.37 (m, 2H), 0.90 (t, 1:7.2, bromide 
| \ 
\ / l Br N 
/ 
N 
I \ N @ \ 
/ B e I N r / 
3H); l3CNMR, 158.19, 143.98, 138.11, 131.53, 128.69, 50 3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to 
128-05, 119-45, 83-11, 5950, 3584, 3354, 2312, 22-62, 3-picoline (5 ml), and the mixture was heated at 50 C over 
20'77’ 1735’ 14'23' night. The excess picoline was removed in vacuum, and the 
resulting residue was partitioned between water and ether. 
Example 28 55 The aqueous layer was washed extensively with ether until no 
picoline left in the aqueous layer, and then the aqueous layer 
Synthesis of 1-[4-(4-buty1-pheny1)-but-3-yny1]-3_(3_ was extracted with chloroform. The chloroform was removed 
hydroxy-propyl)-pyridinium bromide to afford the product (65%). lHNMR (300 MHZ, CDCl3, 
60 ppm), 9.36 (s, 1H), 9.22 (d, 1:5.4, 1H), 8.44 (br, 2H), 8.21 (d, 
1:75, 1H), 7.97 (m, 1H), 7.54 (d, 7.2, 1H), 7.24-7.24 m, 1H), 
OH 4.96 (t, 1:7.2, 2H), 2.58-2.65 M, 5H), 2.00-2.07 (m, 4H), 
| 1.58-1.60 (m, 2H), 1.20-1.36 (m, 16H); 13CNMR, 148.76, 
: Br N / 65 146.10, 145.58, 144.77, 142.38, 139.83, 137.29, 127.80, 
/ \/ < > \/ ACNW?HX 123.98, 62.28, 58.71, 33.31, 32.36, 31.32, 29.80, 29.74, 
29.64, 29.38, 29.35, 26.45, 1915,1881. 
US 8,846,937 B2 
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Example 30 
Synthesis of Compound 3,4-dimethyl-1-(13 -pyridin 
3 -yl-tridecyl)-pyridinium bromide 
I \ 
I \ Br N/ 
/ 
N 
\ N@\ 
l / Br, I / 
3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to 2.21 (br, 1H), 1.82-2.02 (m, 2H), 1.54-1.62 (m, 2H), 1.15 
3,4-lutidine (5 ml), and the mixture was heated at 50 C over- 135 (by, 12H), l3CNMR3 157,61, 149.68, 146.92, 143.35, 
night. The excess picoline was removed in a vacuum, and the 20 141 _91, 13845, 13833, 13632, 12855, 12357, 6137, 
resulting residue was Partitioned between water and ether- 33.31, 32.19, 31.41, 29.85, 29.80, 29.68, 29.41, 26.45, 20.69, 
The aqueous layer was washed extensively with ether until no 17_ 40_ 
3,4-lutidine was left in the aqueous layer, and then the aque 
ous layer was extracted with chloroform. The chloroform was 
removed to afford the product (60%). lHNMR (300 MHZ, Example 31 
coc13, ppm), 9.23 (s, 1H), 9.04 (d, 1:6.3, 1H), 8.40 (br, 2H), 25 
7.79 (d, 1:6.0, 1H), 7.48 (d, 8.1, 1H), 7.18-7.20 (m, 1H), 4.83 Synthesis of Compound 3,5-dimethyl-1-(13-pyridin 
(t, 1:7.5, 2H), 2.58 (t, 1:7.5, 2H), 2.52 (s, 3H), 2.49 (s, 3H), 3-yl-tridecyl)-pyridinium bromide 
| \ 
\ Br / I N 
/ 
N 
I \ N a \ 
/ B 9 I N r / 
40 
3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to 
3,5-lutidine (5 ml), and the mixture was heated at 50 C over 
night. The excess picoline was removed in a vacuum, and the 
resulting residue was partitioned between water and ether. 
45 The aqueous layer was washed extensively with ether until no 
3,5-lutidine was left in the aqueous layer, and then the aque 
ous layer was extracted with chloroform. The chloroform was 
removed to afford the product (62%). lHNMR (300 MHZ, 
CDCl3, ppm), 9.10 (s, 2H), 8.45 (br, 2H), 7.96 (s, 1H), 7.57 
(d, 1:7.5, 1H), 7.24-7.27 (m, 1H), 4.89 (t, 1:7.5, 2H), 2.59 
50 2.54 (m, 8H), 1.99-2.04 (m, 2H), 1.57-1.62 (m, 2H), 1.21 
1.38 (m, 18H), l3CNMR, 148.07, 146.11, 145.45, 141.94, 
139.01, 137.96, 124.16, 62.13, 58.74, 33.29, 32.34, 31.26, 
29.76, 29.73, 29.62, 29.39, 29.30, 26.49, 18.98, 18.82. 
55 Example 32 
Synthesis of Compound 2-(13-pyridin-3-yl-tridecyl) 
5 ,6,7,8-tetrahydro -isoquinolinium bromide 
US 8,846,937 B2 
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3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to 
5,6,7,8-tetrahydro-isoquinoline (5 ml), and the mixture was 
heated at 50 C overnight. The resulting residue was treated 
with ether, and the ether was decanted after deposition for 30'. 
The residue was partitioned between water and ether. The 
aqueous layer was washed extensively with ether, and then 
the aqueous layer was extracted with chloroform. The chlo 
roform was removed to afford the product (62%). lHNMR 
(300 MHZ, CDCl3, ppm), 9.22 (s, 1H), 8.90 (d, 1:6.3, 1H), 
8.44 (br, 2H), 7.67 (d, 1:6.3, 1H), 7.55 (d, 8.1, 7.24-7.28 (m, 
1H), 4.83 (t, 1:7.2, 2.98-3.01 (m, 4H), 2.60 (t, 1:7.8, 2H), 
1.94-2.02 (m, 2H), 1.87-1.90 (m, 4H), 1.56-1.60 (m, 2H), 
1.19-1.35 (br, 20H); l3CNMR, 157.87, 148.79, 146.13, 
144.20, 140.68, 138.95, 138.80, 137.26, 128.08, 123.92, 
61.40, 58.62, 33.30, 32.20, 31.34, 29.94, 29.82, 29.77, 29.67, 
29.42, 29.36, 26.71, 26.46, 21.40, 18.81. 
Example 33 
Synthesis of Compound 5-(1,1'-biphenyl-4-yl)-pent 
4-yn-1-ol 
I Br 
OH % 
4-Bromobiphenyl (10.28 g, 44.10 mmol), 4-pentyn-1-ol 
(4.45 g, 52.92 mmol), and bis(triphenylphosphine)palladium 
(ll) dichloride (310 mg, 0.44 mmol) were stirred in triethy 
lamine (100 mL) under nitrogen for 5 min. Copper(l) iodide 
(42 mg, 0.22 mmol) was added, and the mixture was stirred 
for 4 hrs at 65° C. The mixture was cooled to room tempera 
ture and ?ltered through a celite pad, rinsed with ethylacetate. 
The combined ?ltrate was evaporated to dryness under 
reduced pressure. The resulting residue was puri?ed by col 
umn chromatography (hexanes:ethylacetate 3:2) to afford 
7.78 g ofthe title compound. Yield: 75%. 1H NMR (300 MHZ, 
CDC13) 6 1.88 (m, 2H), 2.57 (t, 1:6.9 HZ, 2H), 3.84 (t, 1:6.0 
HZ, 2H), 7.32-7.60 (m, 9H) ppm; 13C NMR (75 MHZ, CDC13) 
6 16.4, 31.7, 62.1, 81.2, 90.2, 122.8, 127.0, 127.1, 127.6, 
128.9, 132.0, 140.1 ppm. 
20 
25 
30 
35 
40 
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Example 34 
Synthesis of Compound 
4-(5-bromo-pent-1-ynl)-1,1'-biphenyl 
OH % 
Br % 
5-(1,1'-biphenyl-4-yl)-4-pentyn-1-ol (3 .40 g, 14.39 mmol) 
and carbon tetrabromide (6.21 g, 18.71 mmol) were dissolved 
in dry methylene chloride (20 mL) and cooled to 0° C. Triph 
enyl phosphine (5.15 g, 19.65 mmol) in methylene chloride 
(10 mL) was added dropwise, and the mixture was stirred for 
1 h at 0° C. The mixture was poured into hexanes (100 mL), 
and then ?ltered through a short silica gel column, washed 
with ethylacetate/hexanes (1/4). The combined organic sol 
vents were evaporated to dryness under reduced pressure. The 
resulting residue was puri?ed by column chromatography 
(hexanes:ethylacetate 30:1) to afford 4.20 g of the title com 
pound. Yield: 97%. 1H NMR (300 MHZ, CDCl3) 6 2.15 (m, 
2H), 2.63 (t, 1:6.9 HZ, 2H), 3.60 (t, 1:6.3 HZ, 2H), 7.32-7.60 
(m, 9H) ppm; 13C NMR (75 MHZ, CDC13) 6 18.5, 31.8, 32.8, 
81.7, 88.8, 122.6, 127.0, 127.1, 127.6, 128.9, 132.1, 140.5, 
140.6 ppm. 
Example 35 
Synthesis of Compound 1-[5-(1,1'-biphenyl-4-yl) 
pent-4-ynyl] -2-methyl-pyridinium bromide 



















